Villere ST Denis J & Co. LLC lowered its stake in shares of Alpha Cognition Inc. (NASDAQ:ACOG – Free Report) by 11.1% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 63,838 shares of the company’s stock after selling 7,940 shares during the quarter. Villere ST Denis J & Co. LLC owned approximately 0.40% of Alpha Cognition worth $596,000 as of its most recent filing with the Securities and Exchange Commission.
Separately, Salem Investment Counselors Inc. acquired a new stake in shares of Alpha Cognition during the first quarter worth approximately $230,000.
Alpha Cognition Price Performance
Alpha Cognition stock opened at $7.02 on Friday. The company has a market cap of $146.72 million, a PE ratio of -4.39 and a beta of 2.63. The company has a fifty day moving average price of $8.36 and a two-hundred day moving average price of $8.05. Alpha Cognition Inc. has a 12 month low of $3.75 and a 12 month high of $11.54.
Wall Street Analyst Weigh In
Separately, Wall Street Zen raised shares of Alpha Cognition from a “sell” rating to a “hold” rating in a research report on Saturday, August 30th. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $20.00.
Check Out Our Latest Stock Analysis on Alpha Cognition
Insiders Place Their Bets
In related news, Director Robert James Wills bought 15,000 shares of the business’s stock in a transaction on Monday, August 18th. The shares were bought at an average cost of $8.49 per share, for a total transaction of $127,350.00. Following the completion of the purchase, the director owned 15,000 shares of the company’s stock, valued at $127,350. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Phillip Joseph Mertz sold 27,778 shares of the firm’s stock in a transaction on Monday, August 18th. The shares were sold at an average price of $9.00, for a total value of $250,002.00. Following the completion of the sale, the director owned 22,462 shares in the company, valued at $202,158. The trade was a 55.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.00% of the company’s stock.
Alpha Cognition Company Profile
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
See Also
- Five stocks we like better than Alpha Cognition
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 Heavily Shorted Stocks That Could Pop on Rate Cuts
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Broadcom Gets Second $420 Target as CPO Win Boosts Outlook
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can
Receive News & Ratings for Alpha Cognition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Cognition and related companies with MarketBeat.com's FREE daily email newsletter.